Skip to main content
Shenzhen Bioeasy Biotechnology Co., Ltd. logo

Shenzhen Bioeasy Biotechnology Co., Ltd. — Investor Relations & Filings

Ticker · 300942 ISIN · CNE100004C78 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 910 across all filing types
Latest filing 2025-08-27 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300942

About Shenzhen Bioeasy Biotechnology Co., Ltd.

https://www.bioeasy.com

Shenzhen Bioeasy Biotechnology Co., Ltd. specializes in the development, production, and marketing of rapid testing solutions for food safety, clinical diagnosis, and animal health. The company provides a comprehensive portfolio of diagnostic products, including rapid test strips, enzyme-linked immunosorbent assay (ELISA) kits, and automated detection instruments. Its core focus areas include the detection of antibiotic residues, mycotoxins, pesticides, and foodborne pathogens in dairy, meat, seafood, and grain products. In the clinical sector, Bioeasy offers point-of-care testing (POCT) solutions for infectious diseases and chronic conditions. The company emphasizes research and development to deliver high-sensitivity, user-friendly diagnostic tools that meet international quality standards. Its products are utilized by food producers, regulatory agencies, and healthcare providers to ensure safety and quality control across the global supply chain.

Recent filings

Filing Released Lang Actions
监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of Shenzhen Easy Biological Technology Co., Ltd. It details the meeting held on August 27, 2025, including the approval of the 2025 semi-annual report and related matters such as the use of raised funds, amendments to the company charter, and asset sales by a subsidiary. The document does not contain the actual semi-annual report or financial statements but rather the Supervisory Board's approval and summary of decisions. It also references that the full reports are available on an external website (巨潮资讯网). The document length is short (2027 characters) and serves as an official announcement of meeting resolutions and approvals, not the report itself. Therefore, it fits best into the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2025-08-27 Chinese
关于募投项目结项并将节余募集资金永久补充流动资金的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from Shenzhen Yirui Biotechnology Co., Ltd. regarding the completion of fundraising projects and the permanent supplementation of surplus raised funds into working capital. It details the amounts raised from an IPO and convertible bonds, the management and use of these funds, reasons for surplus funds, and the plan to use the surplus funds. It includes references to regulatory approvals, board and supervisory committee meetings, and a sponsor's verification opinion. The document is structured as a formal announcement to shareholders and the public about the status and use of raised funds, not a full financial report or audit. It does not contain comprehensive financial statements or detailed financial analysis typical of Annual Reports (10-K) or Interim Reports (IR). It is not a call transcript, earnings release, or management report. The document is a regulatory announcement about fundraising project completion and fund usage, fitting the category of Capital/Financing Update (CAP). The length (5409 characters) and detailed content support this classification with high confidence.
2025-08-27 Chinese
信息披露制度
Governance Information Classification · 95% confidence The document is titled '信息披露制度' (Information Disclosure System) for Shenzhen Yirui Biotechnology Co., Ltd. It extensively details the company's policies and procedures for information disclosure, including references to laws, regulations, and stock exchange rules. It covers the principles, content, and timing of disclosures, types of reports (annual, interim, quarterly, temporary), and specific disclosure obligations for various corporate events and transactions. The document is a comprehensive internal policy or governance document rather than an actual financial report or announcement. It does not contain financial statements, audit opinions, earnings data, or voting results. It is not a report publication announcement or a certification. It is a governance-related document outlining the company's internal rules and practices for information disclosure. Therefore, the most appropriate classification is Governance Information (CGR). The document length (15,000 characters) and detailed content support this classification with high confidence.
2025-08-27 Chinese
股东会议事规则
Governance Information Classification · 95% confidence The document is titled '股东会股东会议事规则' which translates to 'Rules of Procedure for Shareholders' Meetings' of Shenzhen Easy Diagnosis Biotech Co., Ltd. It extensively details the procedures, rules, and regulations governing the convening, proposal submission, notification, and conduct of shareholders' meetings. It references relevant laws and regulations such as the Company Law, Securities Law, and stock exchange rules. The content is focused on governance and procedural rules rather than financial results, audit opinions, or announcements. It is not a report of financial performance, nor an announcement of voting results or management changes. It is a governance document outlining internal rules and practices related to shareholder meetings. Therefore, the appropriate classification is Governance Information (CGR). The document length (10801 characters) and detailed procedural content support this classification with high confidence.
2025-08-27 Chinese
东兴证券股份有限公司关于深圳市易瑞生物技术股份有限公司募投项目结项并将节余募集资金永久补充流动资金的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed verification opinion from Dongxing Securities regarding the completion of fundraising projects and the permanent supplementation of surplus raised funds into working capital for Shenzhen Yirui Biotechnology Co., Ltd. It includes specifics about the initial public offering (IPO) fundraising, convertible bond issuance, management and use of raised funds, surplus reasons, and approval procedures by the board and supervisory committee. The document is not a full financial report but a regulatory compliance and verification statement related to fundraising and fund usage. It does not contain comprehensive financial statements or quarterly/yearly financial results. It is not an announcement of a report publication but a formal verification opinion. This fits best under the category of Capital/Financing Update (CAP), as it deals with fundraising and capital usage updates.
2025-08-27 Chinese
关于注销募集资金现金管理专用结算账户的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Shenzhen Yirui Biotechnology Co., Ltd. regarding the cancellation of a special settlement account used for cash management of raised funds. It references prior approvals and related announcements but does not contain financial statements or detailed financial data. The document is short (987 characters) and serves as a formal notice about the account cancellation, not a report or detailed financial disclosure. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and miscellaneous filings that do not fit other categories.
2025-08-25 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.